These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22456311)

  • 21. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome.
    Kravariti M; Naka KK; Kalantaridou SN; Kazakos N; Katsouras CS; Makrigiannakis A; Paraskevaidis EA; Chrousos GP; Tsatsoulis A; Michalis LK
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5088-95. PubMed ID: 15985492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Sahin Y; Unluhizarci K; Yilmazsoy A; Yikilmaz A; Aygen E; Kelestimur F
    Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet-endothelial cell adhesion molecule-1 and CD146: soluble levels and in situ expression of cellular adhesion molecules implicated in the cohesion of endothelial cells in idiopathic inflammatory myopathies.
    Figarella-Branger D; Schleinitz N; Boutière-Albanèse B; Camoin L; Bardin N; Guis S; Pouget J; Cognet C; Pellissier JF; Dignat-George F
    J Rheumatol; 2006 Aug; 33(8):1623-30. PubMed ID: 16881117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study.
    Naka KK; Kalantaridou SN; Kravariti M; Bechlioulis A; Kazakos N; Calis KA; Makrigiannakis A; Katsouras CS; Chrousos GP; Tsatsoulis A; Michalis LK
    Fertil Steril; 2011 Jan; 95(1):203-9. PubMed ID: 20684955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity.
    Kahal H; Aburima A; Ungvari T; Rigby AS; Dawson AJ; Coady AM; Vince RV; Ajjan RA; Kilpatrick ES; Naseem KM; Atkin SL
    Clin Endocrinol (Oxf); 2013 Aug; 79(2):252-8. PubMed ID: 23278130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking.
    Luque-Ramírez M; Mendieta-Azcona C; del Rey Sánchez JM; Matíes M; Escobar-Morreale HF
    Eur J Endocrinol; 2009 Mar; 160(3):469-80. PubMed ID: 19139031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
    Luque-Ramírez M; Alvarez-Blasco F; Uriol Rivera MG; Escobar-Morreale HF
    Hum Reprod; 2008 Jul; 23(7):1594-601. PubMed ID: 18375410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1.
    Tan BK; Adya R; Chen J; Farhatullah S; Heutling D; Mitchell D; Lehnert H; Randeva HS
    Cardiovasc Res; 2009 Aug; 83(3):566-74. PubMed ID: 19414528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No relationship between osteoprotegerin concentrations and endothelial dysfunction in non-obese women with and without polycystic ovary syndrome.
    Abali R; Tasdemir N; Alpsoy S; Tasdemir UG; Guzel S; Yuksel MA; Temel Yuksel I; Yilmaz M
    Arch Gynecol Obstet; 2015 May; 291(5):1075-80. PubMed ID: 25280574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome.
    Diamanti-Kandarakis E; Alexandraki K; Piperi C; Aessopos A; Paterakis T; Katsikis I; Panidis D
    Metabolism; 2007 Jan; 56(1):129-34. PubMed ID: 17161235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
    Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
    Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial.
    Agarwal N; Rice SP; Bolusani H; Luzio SD; Dunseath G; Ludgate M; Rees DA
    J Clin Endocrinol Metab; 2010 Feb; 95(2):722-30. PubMed ID: 19996308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endothelial dysfunction in hyperandrogenic polycystic ovary syndrome is not explained by either obesity or ectopic fat deposition.
    Sprung VS; Jones H; Pugh CJ; Aziz NF; Daousi C; Kemp GJ; Green DJ; Cable NT; Cuthbertson DJ
    Clin Sci (Lond); 2014 Jan; 126(1):67-74. PubMed ID: 23826984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS).
    Bilgir O; Kebapcilar L; Taner C; Bilgir F; Kebapcilar A; Bozkaya G; Yildiz Y; Yuksel A; Sari I
    Intern Med; 2009; 48(14):1193-9. PubMed ID: 19602786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
    Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE
    Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
    Kriplani A; Periyasamy AJ; Agarwal N; Kulshrestha V; Kumar A; Ammini AC
    Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome.
    Kuşçu NK; Var A
    Acta Obstet Gynecol Scand; 2009; 88(5):612-7. PubMed ID: 19308750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome.
    Orio F; Palomba S; Cascella T; De Simone B; Di Biase S; Russo T; Labella D; Zullo F; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4588-93. PubMed ID: 15356067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endothelial function and its relationship to leptin, homocysteine, and insulin resistance in lean and overweight eumenorrheic women and PCOS patients: a pilot study.
    Mancini F; Cianciosi A; Reggiani GM; Facchinetti F; Battaglia C; de Aloysio D
    Fertil Steril; 2009 Jun; 91(6):2537-44. PubMed ID: 18462732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.